FDA Approvals, In Brief: Novartis’ Meningitis Vaccine Bexsero Gets Early Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
Also, Rockwell’s iron deficiency treatment Triferic gains agency approval, but without a dose-sparing claim related to erythropoiesis-stimulating agents; Symplmed’s perindopril/amlodipine fixed-dose combination approved for hypertension.
You may also be interested in...
Keeping Track: DMD, RMAT, HIV, BTDs, Tc-99m – FTW
The latest drug development news and highlights from our US FDA Performance Tracker.
Rockwell Sees Opportunity For Triferic In Cost-Sensitive CKD Market
Rockwell Medical has filed an NDA for the iron replacement therapy, which will be positioned as an alternative to I.V. iron during dialysis and could limit the need for erythropoietin-stimulating agents.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.